Video
Revisit Every OncLive On Air Episode From May 2024
D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor
Additional 3 Years of Adjuvant Imatinib Maintenance Reduces Recurrence Risk in High-Risk GIST
Somaiah Shares Insight on the Changing Landscapes of GIST, TGCT, and RAS/RAF-Mutant Tumors
Examining Potential Markers of Osteosarcoma Stem Cells Is at the Forefront of Research
FAK Inhibition Emerges as a Potential Complementary Treatment Pathway
Asciminib Bests Standard-of-Care TKIs in Ph+ CML
Lorlatinib Yields Longest Reported PFS in Advanced NSCLC
Rivoceranib Plus Camrelizumab Maintains Frontline Survival Benefit in Unresectable HCC
Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma